These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38310565)

  • 1. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
    Ghosh S; Feagan BG; Ott E; Gasink C; Godwin B; Marano C; Miao Y; Ma T; Loftus EV; Sandborn WJ; Danese S; Abreu MT; Sands BE
    J Crohns Colitis; 2024 Aug; 18(7):1091-1101. PubMed ID: 38310565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.
    Sandborn WJ; Feagan BG; Danese S; O'Brien CD; Ott E; Marano C; Baker T; Zhou Y; Volger S; Tikhonov I; Gasink C; Sands BE; Ghosh S
    Inflamm Bowel Dis; 2021 Jun; 27(7):994-1007. PubMed ID: 32964215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
    Ghosh S; Gensler LS; Yang Z; Gasink C; Chakravarty SD; Farahi K; Ramachandran P; Ott E; Strober BE
    Drug Saf; 2019 Jun; 42(6):751-768. PubMed ID: 30739254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
    Afif W; Arasaradnam RP; Abreu MT; Danese S; Sandborn WJ; Miao Y; Zhang H; Panaccione R; Hisamatsu T; Scherl EJ; Leong RW; Rowbotham DS; Peyrin-Biroulet L; Sands BE; Marano C
    Am J Gastroenterol; 2024 May; 119(5):910-921. PubMed ID: 38095692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
    Li K; Friedman JR; Chan D; Pollack P; Yang F; Jacobstein D; Brodmerkel C; Gasink C; Feagan BG; Sandborn WJ; Rutgeerts P; De Hertogh G
    Gastroenterology; 2019 Oct; 157(4):1019-1031.e7. PubMed ID: 31279870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
    Adedokun OJ; Xu Z; Marano C; O'Brien C; Szapary P; Zhang H; Johanns J; Leong RW; Hisamatsu T; Van Assche G; Danese S; Abreu MT; Sands BE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2244-2255.e9. PubMed ID: 31816446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
    Hanauer SB; Sandborn WJ; Feagan BG; Gasink C; Jacobstein D; Zou B; Johanns J; Adedokun OJ; Sands BE; Rutgeerts P; de Villiers WJS; Colombel JF; Ghosh S
    J Crohns Colitis; 2020 Jan; 14(1):23-32. PubMed ID: 31158271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
    Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
    N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
    Panaccione R; Danese S; Sandborn WJ; O'Brien CD; Zhou Y; Zhang H; Adedokun OJ; Tikhonov I; Targan S; Abreu MT; Hisamatsu T; Scherl EJ; Leong RW; Rowbotham DS; Arasaradnam RP; Sands BE; Marano C
    Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1658-1675. PubMed ID: 33086438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Honap S; Meade S; Ibraheim H; Irving PM; Jones MP; Samaan MA
    Dig Dis Sci; 2022 Mar; 67(3):1018-1035. PubMed ID: 33723700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
    Adedokun OJ; Xu Z; Gasink C; Kowalski K; Sandborn WJ; Feagan B
    Clin Ther; 2022 Oct; 44(10):1336-1355. PubMed ID: 36150926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review.
    Fang S; Zhang S; Zhang C; Wang L
    Paediatr Drugs; 2023 Sep; 25(5):499-513. PubMed ID: 37528211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
    Dayan JR; Dolinger M; Benkov K; Dunkin D; Jossen J; Lai J; Phan BL; Pittman N; Dubinsky MC
    J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
    Colombel JF; Sands BE; Gasink C; Yeager B; Adedokun OJ; Izanec J; Ma T; Gao LL; Lee SD; Targan SR; Ghosh S; Hanauer SB; Sandborn WJ
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):144-153.e2. PubMed ID: 37391056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
    Abreu MT; Rowbotham DS; Danese S; Sandborn WJ; Miao Y; Zhang H; Tikhonov I; Panaccione R; Hisamatsu T; Scherl EJ; Leong RW; Arasaradnam RP; Afif W; Peyrin-Biroulet L; Sands BE; Marano C
    J Crohns Colitis; 2022 Aug; 16(8):1222-1234. PubMed ID: 35239968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.